Ruthenium(ii) and palladium(ii) homo- and heterobimetallic complexes: synthesis, crystal structures, theoretical calculations and biological studies. 2019

Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
Department of Chemistry, University of Isfahan, Isfahan 81746-73441, Iran. h.a.rudbari@sci.ui.ac.ir hamiri1358@gmail.com.

Four Ru-Pd heterobimetallic complexes, each one in two different coordination modes (NNSS and NS) having metals connected by a binucleating dialkyldithiooxamidate [N(R)SC-CS(R)N] [R = methyl, ethyl, n-butyl and isopropyl], were prepared by reacting the monochelate [(trinpropyl-phosphine)ClPd(HR2C2N2S2κ-S,S-Pd)] with [(η6-p-cymene)RuCl2]2. Furthermore, two palladium homobimetallic complexes having two (trinpropyl-phosphine)ClPd moieties joined by a diethyldithiooxamidate in both κ-N,S Pd, κ-N',S' Pd' and κ-N,N' Pd, κ-S,S' Pd' coordination modes were synthesized. For both kinds of complexes, homo- and heterobimetallic, at room temperature and in chloroform solution, the NNSS coordination mode (kinetic compounds) turns out to be unstable and therefore the resulting complexes rearrange into a thermodynamically more stable form (NS coordination mode). The crystal structures of [(trinpropyl-phosphine)ClPd]2[μ-(ethyl)2-DTO κ-N,S Pd, κ-N',S' Pd'] (2) and [(η6-p-cymene)ClRu][μ-(methyl)2-DTO κ-N,S Ru, κ-N,S Pd] [(trinpropyl-phosphine)ClPd] (1c) were determined by solid state X-ray crystallography. Moreover, the higher stability of the thermodynamic species in the heterobimetallic complexes (Ru-Pd) was evaluated by means of computational studies in accordance with the maximum hardness principle. All stable NS complexes (i.e.1c-4c, 2 and the previously reported homobimetallic Ru complex 3) were tested against two leukemia cell lines, namely the drug-sensitive CCRF-CEM cell line and its multidrug-resistant sub-cell line CEM/ADR5000 showing anti-proliferative activity in the low micromolar range (∼1-5 μM) and micromolar range (∼10-25 μM), respectively. In addition, these complexes efficaciously block at least two out of the three proteolytic activities of the tumor target 20S proteasome, with heterobimetallic complex 3c and homobimetallic complex 3 possessing the best inhibitory profile.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010165 Palladium A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003460 Crystallization The formation of crystalline substances from solutions or melts. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Crystalline Polymorphs,Polymorphism, Crystallization,Crystal Growth,Polymorphic Crystals,Crystal, Polymorphic,Crystalline Polymorph,Crystallization Polymorphism,Crystallization Polymorphisms,Crystals, Polymorphic,Growth, Crystal,Polymorph, Crystalline,Polymorphic Crystal,Polymorphisms, Crystallization,Polymorphs, Crystalline
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000497 Alloys A mixture of metallic elements or compounds with other metallic or metalloid elements in varying proportions. Alloy
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012428 Ruthenium A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
November 2009, Dalton transactions (Cambridge, England : 2003),
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
November 2021, European journal of medicinal chemistry,
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
October 2009, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy,
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
August 2008, Inorganic chemistry,
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
December 2008, Inorganic chemistry,
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
January 2021, Medicinal chemistry (Shariqah (United Arab Emirates)),
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
April 2021, Dalton transactions (Cambridge, England : 2003),
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
February 2019, Inorganic chemistry,
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
June 2023, Molecules (Basel, Switzerland),
Banafshe Askari, and Hadi Amiri Rudbari, and Nicola Micale, and Tanja Schirmeister, and Thomas Efferth, and Ean-Jeong Seo, and Giuseppe Bruno, and Kevin Schwickert
February 2017, ChemPlusChem,
Copied contents to your clipboard!